Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Fort Worth, Texas 76134


The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic atrophy.

Study summary:

This study consists of an up-to 30-day screening period, an approximately 336-day treatment period, and a follow-up period consisting of two visits occurring 4 and 16 weeks after the last administered injection.


Inclusion Criteria: - Sign written informed consent form; - Geographic atrophy in both eyes; - Other protocol-specified inclusion criteria may apply. Exclusion Criteria: - Pregnant or lactating women and women of child-bearing potential; - Any medical condition (systemic or ophthalmic) that may preclude the safe administration of test article or safe participation in this study; - Any contraindications or hypersensitivities to any component of the LFG316 or CLG561 solution; - Any contraindications to IVT injections; - Ocular surgery in either eye within 90 days of screening; - Uncontrolled ocular hypertension or glaucoma in the study eye; - Other protocol-specified exclusion criteria may apply.



Primary Contact:

Study Director
Sr Clinical Manager, Pharma, GCRA
Alcon Research

Backup Contact:


Location Contact:

Fort Worth, Texas 76134
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.